Halozyme Therapeutics, Inc.
HALO
$71.48
$0.751.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 348.84M | 316.89M | 595.49M | 557.28M | 485.36M |
| Total Depreciation and Amortization | 101.34M | 88.05M | 81.79M | 81.73M | 81.56M |
| Total Amortization of Deferred Charges | 7.91M | 7.51M | 7.40M | 7.38M | 7.37M |
| Total Other Non-Cash Items | 405.26M | 391.37M | 43.78M | 14.51M | 32.93M |
| Change in Net Operating Assets | -185.93M | -152.26M | -117.46M | -113.12M | -103.36M |
| Cash from Operations | 677.42M | 651.56M | 611.00M | 547.78M | 503.86M |
| Capital Expenditure | -9.76M | -6.97M | -8.60M | -7.08M | -8.10M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -725.26M | -725.97M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 276.75M | 187.12M | 234.05M | -136.56M | -262.36M |
| Cash from Investing | -458.27M | -545.81M | 225.46M | -143.64M | -270.46M |
| Total Debt Issued | 1.47B | 1.47B | -- | -- | -- |
| Total Debt Repaid | -845.43M | -845.43M | -- | -- | -- |
| Issuance of Common Stock | 21.83M | 21.83M | 21.27M | 23.35M | 31.63M |
| Repurchase of Common Stock | -340.66M | -342.37M | -592.37M | -553.49M | -253.32M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -389.21M | -389.21M | -- | -- | -- |
| Cash from Financing | -83.47M | -85.17M | -571.10M | -530.14M | -221.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 135.68M | 20.57M | 265.35M | -126.00M | 11.70M |